National Drug Abuse Treatment 

 CALIFORNIA/ARIZONA NODE


CALIFORNIA/ARIZONA NODE

James L. Sorensen, Ph.D. [email]
Principal Investigator

Adjunct Professor
Langly Porter Psychiatric Institute
UCSF San Francisco General Hospital
1001 Potrero Ave., Building 20, Ste 2117, Box 0852
San Francisco, CA 94110
http://psych.ucsf.edu/research.aspx?id=1316 (Node)
http://www.nida.nih.gov/CTN/centers/california.html (NIDA)

The California/Arizona Node joined the Clinical Trials Network in September 2002. This Node represents a partnership between researchers at the University of California, San Francisco General Hospital (the Regional Research and Training Center) and the University of Arizona, in collaboration with six CTPs operating in both urban and rural locations (San Francisco, Oakland, Sacramento, and Tucson areas). Participating CTPs, several of which have multiple sites, include hospital-based and community-based programs, and include residential, outpatient, and methadone treatment approaches. Collectively, these six CTPs serve a racially and ethnically diverse population of more than 16,000 patients per year.


 Find publications in the Library with California/Arizona Node involvement

 

  CALIFORNIA/ARIZONA NODE PROTOCOL INVOLVEMENT
CTN-0008 Assessment of the National Drug Abuse Clinical Trials Network: A Baseline for Investigating Diffusion of Innovation
CTN-0012 Characteristics of Screening, Evaluation, and Treatment of HIV/AIDS, Hepatitis C Viral Infections, and Sexually Transmitted Infections in Substance Abuse Treatment Programs
CTN-0014 Brief Strategic Family Therapy for Adolescent Drug Abusers
CTN-0014-A-1 Mediators and Moderators of Brief Strategic Family Therapy (BSFT) for Adolescent Drug Use
CTN-0018 Reducing HIV/STD Risk Behaviors: A Research Study for Men in Drug Abuse Treatment

CTN-0020 Job Seekers Training for Patients with Drug Dependence
CTN-0027 Starting Treatment with Agonist Replacement Therapies (START)
CTN-0027-A-1 START Pharmacogenetics: Exploratory Genetic Studies in Starting Treatment with Agonist Replacement Therapies
CTN-0027-A-2 Retention of Suboxone Patients in START: Perspectives of Providers and Patients
CTN-0030

Prescription Opioid Addiction Treatment Study (POATS)
CTN-0030-A-1 Collection of Economic Data for the Prescription Opioid Addiction Treatment Study

CTN-0031-A-3 Organizational and Practitioner Influences on Implementation of STAGE-12
CTN-0032 HIV Rapid Testing and Counseling

CTN-0032-A-1 Economic Analysis of HIV Rapid Testing in Drug Abuse Treatment Programs
CTN-0035-Ot Access to HIV and Hepatitis Screening and Care Among Ethnic Minority Drug Users In and Out of Drug Treatment

CTN-0038-Ot Barriers to Substance Abuse Treatment Among Asian Americans and Pacific Islanders
CTN-0043-S Substance Abuse Treatment Outcomes in Racial/Ethnic Minority Populations
CTN-0045-Ot Rates of HIV Testing and Barriers to Testing in African Americans Receiving Substance Abuse Treatment
CTN-0046 Smoking Cessation and Stimulant Treatment (S-CAST): Evaluation of the Impact of Concurrent Outpatient Smoking Cessation and Stimulant Treatment on Stimulant Dependence

 


 

 

 

  

 
Supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol and Drug Abuse Institute.
The materials on this site have neither been created nor reviewed by NIDA.
Updated 7/2010 -- http://ctndisseminationlibrary.org/nodes/caaznode.htm
info@ctndisseminationlibrary.org